Charcot-Marie-Tooth Disease: Genetic Causes, Types, and Management Strategies

Charcot-Marie-Tooth (CMT) disease encompasses a heterogeneous group of inherited peripheral neuropathies affecting approximately 1 in 2,500 individuals. These disorders damage both motor and sensory nerves, leading to progressive distal weakness, sensory loss, and characteristic physical changes.

Genetic Classification: Major Subtypes

Over 100 genes have been implicated in CMT, with inheritance patterns including autosomal dominant (AD), autosomal recessive (AR), and X-linked (XL). Genetic testing is essential for definitive diagnosis, prognosis, and family counseling. The table below summarizes the most common subtypes:

Clinical Hallmarks

• Distal muscle wasting producing "stork legs" or "inverted champagne bottle" calves.
• Foot deformities: pes cavus (high arches), hammer toes, and foot drop.
• Gait abnormalities: steppage gait with frequent tripping.
• Sensory loss in a stocking-glove distribution.
• Hand weakness with thenar wasting appearing later in the disease course.
• Absent deep tendon reflexes throughout.

Multidisciplinary Management

• Physical and occupational therapy: Stretching, strengthening, ankle-foot orthoses (AFOs), and assistive devices to maintain mobility.
• Orthopedic interventions: Tendon transfers and osteotomies for fixed deformities.
• Pain management: Neuropathic agents such as gabapentin or duloxetine.
• Genetic counseling: Recurrence risk assessment, prenatal and preimplantation testing options.
• Surveillance: Pulmonary function (rare diaphragmatic involvement) and cardiac monitoring (certain subtypes).

Emerging Therapies

Investigational approaches include gene therapy (AAV-delivered PMP22 shRNA for CMT1A), antisense oligonucleotides, and small molecules targeting proteostasis — several now in clinical trials.

While CMT is lifelong, early and comprehensive intervention preserves function and independence for the majority of patients.